ClinicalTrials.gg

Program

zemocimig

A development code. Also written as “NXT007”.

Its studies are mostly in Hemophilia A, led by Hoffmann-La Roche.

Furthest: phase 3, since Feb 11, 20265 company-led studies, 4 open or runningNext primary completion: Sep 23, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche54 open or runningphase 3since Feb 11, 2026Aug 4, 2023Sep 23, 2027phase 3 · NCT07416526
  • Named in Hoffmann-La Roche’s own pipeline as RG6512 zemocimig (NXT007), phase 3, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2023First study: phase 2 study in Hemophilia AFirst studyNCT05987449 · 60 planned · United States, Canada, Italy and more
  2. Dec 11, 2023Phase 1 study in Healthy Male ParticipantsNCT06189508 · 48 enrolled · New Zealand
  3. Feb 11, 20262 phase 3 studies in Hemophilia APhase 3 reachedNCT07416604, NCT07416526
  4. Sep 17, 2026Phase 3 study in Hemophilia ANCT07838194 · 50 planned · Japan

Ahead

  1. Sep 23, 2027Primary completion: phase 3 study in Hemophilia ANCT07416526
  2. Feb 29, 2028Primary completion: phase 3 study in Hemophilia ANCT07416604
  3. Sep 30, 2028Primary completion: phase 3 study in Hemophilia ANCT07838194
  4. Dec 11, 2033Primary completion: phase 2 study in Hemophilia ANCT05987449

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07838194Hemophilia A · Japan3RecruitingSep 30, 202850
NCT07416604Hemophilia A · United States, Argentina, Australia and more3RecruitingFeb 29, 2028360
NCT07416526Hemophilia A · United States, Argentina, Austria and more3RecruitingSep 23, 2027138
NCT06189508Healthy Male Participants · New Zealand1CompletedDec 22, 202448
NCT05987449Hemophilia A · United States, Canada, Italy and more2RecruitingDec 11, 203360

How it is read

Names in the registry

  • “NXT007”, 5 entries

Codes read as this program: NXT007.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.